RXRX
Recursion Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.63
+5.52%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 33.94x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- 2.12x
- Price / sales
- 35.43x
- Price / cash flow
- -5.54x
Enterprise value
- Enterprise value
- $1.5B
- EV / sales
- 26.61x
- EV / EBITDA
- -3.28x
- EV / EBIT
- -2.68x
- Market cap
- $1.9B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026